Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2019-08-16 Earnings Release
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 16, 2019, by Moleculin Biotech, Inc. It announces the issuance of a press release containing financial results for the quarter ended June 30, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a notification of the earnings release. Given the document length is only 3168 characters and it primarily announces the earnings press release, it fits the definition of an Earnings Release (ER) announcement rather than a full financial report or other filing types. Therefore, the correct classification is Earnings Release (ER).
2019-08-16 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-16 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company's Quarterly Report on Form 10-Q for the period ended June 30, 2019 could not be filed on time and explains the reasons for the delay. The document does not contain the actual financial statements or substantive financial data of the 10-Q report but is rather a notification about the delay in filing that report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not contain the report itself.
2019-08-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text includes a press release about a clinical trial enrollment milestone and explicitly states it is a press release (Exhibit 99.1). There are no financial statements or detailed financial data presented, only an announcement of a corporate event. The document length is 3713 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, such filings are best categorized under Regulatory Filings (RNS) as they do not contain comprehensive financial data or detailed reports but are regulatory announcements of material events.
2019-08-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 6, 2019, by Moleculin Biotech, Inc. It announces a press release about a scientific paper presentation at a conference. The document is short (3791 characters) and primarily serves as a disclosure of a press release rather than containing detailed financial data or substantive report content. It does not contain financial statements or detailed analysis but rather a regulatory announcement of an event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-08-06 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an At Market Issuance Sales Agreement for selling common stock. This is an update on the company's financing activities, specifically regarding capital raising through stock sales. The document does not contain full financial statements or detailed financial performance data, but rather an announcement of a financing agreement. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6288 characters, which is consistent with a detailed 8-K filing but not a full annual or quarterly report.
2019-07-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.